{"id":384212,"date":"2026-01-15T11:35:45","date_gmt":"2026-01-15T10:35:45","guid":{"rendered":"https:\/\/ga-p.com\/?post_type=publicacion&p=384212"},"modified":"2026-01-15T11:35:48","modified_gmt":"2026-01-15T10:35:48","slug":"excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package","status":"publish","type":"publicacion","link":"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/","title":{"rendered":"Excessive extension of the Bolar clause in the ‘pharmaceutical legislative package’"},"content":{"rendered":"
\n
\n
\n
\n
\n\n

The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.<\/p>\n\n\n\n

\n
\n \"icon\"\n

Download document<\/p>\n<\/div>\n <\/div>\n

\n View document \"icon\"\n <\/a>\n <\/div>\n<\/div>\n\n<\/div>\n<\/div>\n\n\n
\n
\n\n\n
\n\n
\n
\n\n
\n
Autor\/s<\/div>\n
\n

\n <\/span>\n \u00c1ngel Garc\u00eda Vidal<\/span>\n – Academic Counsel<\/span>\n <\/p>\n

\n <\/span>\n Rais Amils<\/a>\n – Partner<\/span>\n <\/p>\n <\/div>\n <\/div>\n \n \n

\n
Category<\/div>\n

\n <\/span>\n Analysis<\/span>\n <\/p>\n <\/div>\n \n

\n
Areas and sectors<\/div>\n

\n <\/span>\n Intellectual Property<\/a>\n <\/p>\n

\n <\/span>\n Life Sciences and Healthcare<\/a>\n <\/p>\n <\/div>\n <\/div>\n<\/div>\n\n<\/div>\n<\/div>\n\n<\/div>\n\n <\/div>\n\n<\/div>\n\n\n

\n
\n
\n
\n
\n\n
\n\n\n
\n See previous \"icon\"\n <\/a>\n See next \"icon\"\n <\/a>\n <\/div>\n <\/div>\n<\/div>\n<\/div>\n\n\n
\n
<\/div>\n<\/div>\n\n<\/div>\n\n <\/div>\n\n<\/div>\n\n\n\n\n
\n
\n
\n
\n
<\/div>\n <\/div>\n <\/div>\n
\n \n
\n
\n \"\u00c1ngel <\/div>\n
\n
\u00c1ngel Garc\u00eda Vidal<\/div>\n
Academic Counsel<\/div>\n
\n
\n \"email\"\n\n agarciav@ga-p.com<\/a>\n <\/div>\n
\n \n Madrid<\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n Corporate and M&A, <\/a>\n Intellectual Property<\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \"icon\"\n\n \"icon\"\n\n <\/div>\n\n \n
\n \n
\n \"Rais <\/div>\n <\/a>\n
\n \n
Rais Amils<\/div>\n <\/a>\n
Partner<\/div>\n
\n \"email\"\n\n ramils@ga-p.com<\/a>\n <\/div>\n
\n \n
\n Intellectual Property<\/a>\n <\/div>\n <\/div>\n
\n \n Barcelona<\/a>\n <\/div>\n
\n \"icon\"\n\n (+34) 93 415 74 00<\/a>\n <\/div>\n <\/div>\n <\/div>\n\n \n
\n \"icon\"\n \"icon\"\n \n <\/div>\n <\/a>\n <\/div>\n <\/div>\n
\n
\n
\n
\n \n
\n
\n \"\u00c1ngel <\/div>\n
\n
\u00c1ngel Garc\u00eda Vidal<\/div>\n
Academic Counsel<\/div>\n
\n
\n \"email\"\n\n agarciav@ga-p.com<\/a>\n <\/div>\n
\n \n Madrid<\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n Corporate and M&A, <\/a>\n Intellectual Property<\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \"icon\"\n\n \"icon\"\n\n <\/div>\n\n <\/div>\n
\n \n
\n \n
\n \"Rais <\/div>\n <\/a>\n
\n \n
Rais Amils<\/div>\n <\/a>\n
Partner<\/div>\n
\n \"email\"\n\n ramils@ga-p.com<\/a>\n <\/div>\n
\n \n
\n Intellectual Property<\/a>\n <\/div>\n <\/div>\n
\n \n Barcelona<\/a>\n <\/div>\n
\n \"icon\"\n\n (+34) 93 415 74 00<\/a>\n <\/div>\n <\/div>\n <\/div>\n\n \n
\n \"icon\"\n \"icon\"\n \n <\/div>\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
<\/div>\n
\n
\n
\"icon\"<\/div>\n
\"icon\"<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.<\/p>\n","protected":false},"featured_media":322569,"template":"","publicacion_categoria":[126],"class_list":["post-384212","publicacion","type-publicacion","status-publish","has-post-thumbnail","hentry","publicacion_categoria-analysis-en"],"acf":[],"yoast_head":"\nExcessive extension of the Bolar clause in the 'pharmaceutical legislative package' - Despacho de abogados G\u00f3mez-Acebo y Pombo<\/title>\n<meta name=\"description\" content=\"The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Excessive extension of the Bolar clause in the 'pharmaceutical legislative package' - Despacho de abogados G\u00f3mez-Acebo y Pombo\" \/>\n<meta property=\"og:description\" content=\"The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/\" \/>\n<meta property=\"og:site_name\" content=\"Despacho de abogados G\u00f3mez-Acebo y Pombo\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-15T10:35:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ga-p.com\/wp-content\/uploads\/2024\/10\/Analysis.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1308\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\\\/\",\"url\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\\\/\",\"name\":\"Excessive extension of the Bolar clause in the 'pharmaceutical legislative package' - Despacho de abogados G\u00f3mez-Acebo y Pombo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ga-p.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Analysis.jpg\",\"datePublished\":\"2026-01-15T10:35:45+00:00\",\"dateModified\":\"2026-01-15T10:35:48+00:00\",\"description\":\"The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ga-p.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Analysis.jpg\",\"contentUrl\":\"https:\\\/\\\/ga-p.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Analysis.jpg\",\"width\":2500,\"height\":1308},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/publications\\\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ga-p.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Excessive extension of the Bolar clause in the ‘pharmaceutical legislative package’\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/ga-p.com\\\/en\\\/\",\"name\":\"Despacho de abogados G\u00f3mez-Acebo & Pombo\",\"description\":\"G\u00f3mez-Acebo y Pombo es una firma de abogados independiente, con experiencia internacional, especializada en todas las \u00e1reas del derecho de los negocio.\",\"publisher\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ga-p.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#organization\",\"name\":\"Despacho de abogados G\u00f3mez-Acebo & Pombo\",\"url\":\"https:\\\/\\\/ga-p.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ga-p.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo-1-1.svg\",\"contentUrl\":\"https:\\\/\\\/ga-p.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo-1-1.svg\",\"caption\":\"Despacho de abogados G\u00f3mez-Acebo & Pombo\"},\"image\":{\"@id\":\"https:\\\/\\\/ga-p.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Excessive extension of the Bolar clause in the 'pharmaceutical legislative package' - Despacho de abogados G\u00f3mez-Acebo y Pombo","description":"The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/","og_locale":"en_US","og_type":"article","og_title":"Excessive extension of the Bolar clause in the 'pharmaceutical legislative package' - Despacho de abogados G\u00f3mez-Acebo y Pombo","og_description":"The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.","og_url":"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/","og_site_name":"Despacho de abogados G\u00f3mez-Acebo y Pombo","article_modified_time":"2026-01-15T10:35:48+00:00","og_image":[{"width":2500,"height":1308,"url":"https:\/\/ga-p.com\/wp-content\/uploads\/2024\/10\/Analysis.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/","url":"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/","name":"Excessive extension of the Bolar clause in the 'pharmaceutical legislative package' - Despacho de abogados G\u00f3mez-Acebo y Pombo","isPartOf":{"@id":"https:\/\/ga-p.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/#primaryimage"},"image":{"@id":"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/#primaryimage"},"thumbnailUrl":"https:\/\/ga-p.com\/wp-content\/uploads\/2024\/10\/Analysis.jpg","datePublished":"2026-01-15T10:35:45+00:00","dateModified":"2026-01-15T10:35:48+00:00","description":"The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.","breadcrumb":{"@id":"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/#primaryimage","url":"https:\/\/ga-p.com\/wp-content\/uploads\/2024\/10\/Analysis.jpg","contentUrl":"https:\/\/ga-p.com\/wp-content\/uploads\/2024\/10\/Analysis.jpg","width":2500,"height":1308},{"@type":"BreadcrumbList","@id":"https:\/\/ga-p.com\/en\/publications\/excessive-extension-of-the-bolar-clause-in-the-pharmaceutical-legislative-package\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ga-p.com\/en\/"},{"@type":"ListItem","position":2,"name":"Excessive extension of the Bolar clause in the ‘pharmaceutical legislative package’"}]},{"@type":"WebSite","@id":"https:\/\/ga-p.com\/en\/#website","url":"https:\/\/ga-p.com\/en\/","name":"Despacho de abogados G\u00f3mez-Acebo & Pombo","description":"G\u00f3mez-Acebo y Pombo es una firma de abogados independiente, con experiencia internacional, especializada en todas las \u00e1reas del derecho de los negocio.","publisher":{"@id":"https:\/\/ga-p.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ga-p.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ga-p.com\/en\/#organization","name":"Despacho de abogados G\u00f3mez-Acebo & Pombo","url":"https:\/\/ga-p.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ga-p.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ga-p.com\/wp-content\/uploads\/2024\/09\/Logo-1-1.svg","contentUrl":"https:\/\/ga-p.com\/wp-content\/uploads\/2024\/09\/Logo-1-1.svg","caption":"Despacho de abogados G\u00f3mez-Acebo & Pombo"},"image":{"@id":"https:\/\/ga-p.com\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/publicacion\/384212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/publicacion"}],"about":[{"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/types\/publicacion"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/media\/322569"}],"wp:attachment":[{"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/media?parent=384212"}],"wp:term":[{"taxonomy":"publicacion_categoria","embeddable":true,"href":"https:\/\/ga-p.com\/en\/wp-json\/wp\/v2\/publicacion_categoria?post=384212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}